Study title and authors:
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.
Books: |
Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky V, Weis S, Shapiro DR, Beere PA, Gotto AM.
Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, USA.
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/11348605
This study examined the effects of 20 to 40 mg/day of lovastatin in 6,605 generally healthy middle-aged and older men and women. 3,304 people received the statin drug and 3,301 people received a placebo.
The study found that the statin drug reduced the risk of a first acute major coronary event by 37%. However the statin drug also increased cancer rates by 41% and increased the overall death rate by 4%.
More information on this subject: Books : Scientific Studies : Other Websites : Videos : Food Mall